Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > "to the market"; "commercialization or licensing"
View:
Post by prophetoffactz on Jun 05, 2024 7:07pm

"to the market"; "commercialization or licensing"

From the news release:
 
“With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.”


"Cash from these products is planned to be used along with the Company’s revenue from the commercialization or licensing of its macimorelin product to support the development of exciting, high potential-return products, ideally creating growing and sustainable revenue for the Company and investors."

"and constantly looking for strategic growth opportunities.”
Comment by prophetoffactz on Jun 05, 2024 7:09pm
Does Ronnie want to build Canada's Roche?
Comment by prophetoffactz on Jun 06, 2024 8:34am
AEZS news release: "Cash from these products is planned to be used along with the Company’s revenue from the commercialization or licensing of its macimorelin product..." I asked Perplexity Ai if approval for the pediatric market would enhance potential distribution efficiencies and allow AEZS to distribute the product by tself without a licensee.  --- Yes ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities